These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 38189822)

  • 1. From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy.
    Imodoye SO; Adedokun KA; Bello IO
    Histochem Cell Biol; 2024 Apr; 161(4):299-323. PubMed ID: 38189822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking Tumor Microenvironment to Plasticity of Cancer Stem Cells: Mechanisms and Application in Cancer Therapy.
    Zheng X; Yu C; Xu M
    Front Oncol; 2021; 11():678333. PubMed ID: 34262865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance.
    Zhang A; Miao K; Sun H; Deng CX
    Int J Biol Sci; 2022; 18(7):3019-3033. PubMed ID: 35541919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unlocking the potential of the tumor microenvironment for cancer therapy.
    Tufail M
    Pathol Res Pract; 2023 Nov; 251():154846. PubMed ID: 37837860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
    Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
    Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.
    Zhang J; Tavakoli H; Ma L; Li X; Han L; Li X
    Adv Drug Deliv Rev; 2022 Aug; 187():114365. PubMed ID: 35667465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment: barrier or opportunity towards effective cancer therapy.
    Tiwari A; Trivedi R; Lin SY
    J Biomed Sci; 2022 Oct; 29(1):83. PubMed ID: 36253762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
    Mempel TR; Krappmann D
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-associated macrophages heterogeneity drives resistance to clinical therapy.
    Guo S; Chen X; Guo C; Wang W
    Expert Rev Mol Med; 2022 Apr; 24():e17. PubMed ID: 35400355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment diversity and plasticity in cancer multidrug resistance.
    Li Z; Yin P
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188997. PubMed ID: 37832894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
    Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
    Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
    Buoncervello M; Gabriele L; Toschi E
    Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy.
    Abou Khouzam R; Janji B; Thiery J; Zaarour RF; Chamseddine AN; Mayr H; Savagner P; Kieda C; Gad S; Buart S; Lehn JM; Limani P; Chouaib S
    Semin Cancer Biol; 2023 Dec; 97():104-123. PubMed ID: 38029865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cancer metabolism on therapy resistance - Clinical implications.
    Gonçalves AC; Richiardone E; Jorge J; Polónia B; Xavier CPR; Salaroglio IC; Riganti C; Vasconcelos MH; Corbet C; Sarmento-Ribeiro AB
    Drug Resist Updat; 2021 Dec; 59():100797. PubMed ID: 34955385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic programming and immune suppression in the tumor microenvironment.
    Arner EN; Rathmell JC
    Cancer Cell; 2023 Mar; 41(3):421-433. PubMed ID: 36801000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem cells and tumor heterogeneity: Deciphering the role in tumor progression and metastasis.
    Kapoor-Narula U; Lenka N
    Cytokine; 2022 Sep; 157():155968. PubMed ID: 35872504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-tumor heterogeneity from a cancer stem cell perspective.
    Prasetyanti PR; Medema JP
    Mol Cancer; 2017 Feb; 16(1):41. PubMed ID: 28209166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.
    Li YR; Fang Y; Lyu Z; Zhu Y; Yang L
    J Transl Med; 2023 Oct; 21(1):686. PubMed ID: 37784157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.